Compare iShares MSCI Australia ETF (EWA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Australia ETF trades at $28.27 (market cap $1.17B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 12.3× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWA | NBIX | |
|---|---|---|
Market Cap | $1.17B | $14.36B |
Volume | 2,121,231 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $185.50 |
52-Week Low | $24.95 | $123.10 |
Typical Hold Time | 63 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.23, down 1.12% amid broader Australian market weakness. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent institutional activity includes Squarepoint Ops reducing its stake by 91.2% while other firms like Empowered Funds and Cetera Investment Advisers increased positions. The ETF serves as a commodity proxy, benefiting from Australia's export-driven economy.
The outlook remains cautious with technical weakness and mixed institutional sentiment. Upside potential exists if commodity demand drives Australian equities higher, but near-term risks include persistent inflation concerns and tight monetary policy. The Seeking Alpha buy rating targeting $34.83 suggests over 20% upside potential from current levels.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
